NYSE:SOLV Solventum (SOLV) Stock Price, News & Analysis $88.74 -0.34 (-0.38%) Closing price 11/16/2026 03:59 PM EasternExtended Trading$86.75 -1.99 (-2.24%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Solventum Stock (NYSE:SOLV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Solventum alerts:Sign Up Key Stats Today's Range$88.56▼$89.8350-Day Range$81.35▼$90.5152-Week Range$62.38▼$94.16Volume848,067 shsAverage Volume1.29 million shsMarket Capitalization$15.06 billionP/E Ratio12.60Dividend YieldN/APrice Target$90.27Consensus RatingModerate Buy Company Overview Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration. Solventum serves customers in the United States and international markets. Its business is organized around MedSurg, Dental Solutions and Health Information Systems.AI Generated. May Contain Errors. Read More Solventum Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreSOLV MarketRank™: 1.868256294125 of 5 starsSolventum scored higher than 37% of companies evaluated by MarketBeat, and ranked 789th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingSolventum has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Solventum is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageSolventum has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Solventum's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3.03% Earnings GrowthEarnings for Solventum are expected to grow by 3.03% in the coming year, from $7.26 to $7.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Solventum is 12.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Solventum is 12.60, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.73.Price to Earnings Growth RatioSolventum has a PEG Ratio of 1.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioSolventum has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.97% of the float of Solventum has been sold short.Short Interest Ratio / Days to CoverSolventum has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Solventum has recently increased by 1.93%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSolventum does not currently pay a dividend.Dividend GrowthSolventum does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.80 News SentimentSolventum has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Solventum this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for SOLV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Solventum to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Solventum insiders have not sold or bought any company stock.Percentage Held by Insiders0.24% of the stock of Solventum is held by insiders.Percentage Held by InstitutionsSolventum has minimal institutional ownership at this time.Read more about Solventum's insider trading history. Receive SOLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Solventum and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SOLV Stock News HeadlinesSolventum Corporation (SOLV) - What Are Researchers Saying About This Stock?November 16 at 2:15 AM | americanbankingnews.comWells Fargo & Company Forecasts Strong Price Appreciation for Solventum (NYSE:SOLV) StockNovember 8, 2026 | americanbankingnews.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 17 at 1:00 AM | Profits Run (Ad)Solventum (NYSE:SOLV) Earns Overweight Rating from Piper SandlerNovember 8, 2026 | americanbankingnews.comSolventum (NYSE: SOLV) beats Q3 2026 sales expectationsNovember 7, 2026 | msn.comWhat Is Solventum (SOLV) Signaling With Its 90% Separation And HIS Split Plan?November 7, 2026 | finance.yahoo.comSolventum Corporation Seeks AcquisitionsNovember 6, 2026 | marketscreener.comMSolventum (SOLV) stock trades up, here is whyNovember 6, 2026 | theglobeandmail.comSee More Headlines SOLV Stock Analysis - Frequently Asked Questions How have SOLV shares performed this year? Solventum's stock was trading at $79.25 at the beginning of the year. Since then, SOLV stock has increased by 12.0% and is now trading at $88.7380. How were Solventum's earnings last quarter? Solventum Corporation (NYSE:SOLV) issued its earnings results on Thursday, November, 5th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.11. The business's revenue was down 7.0% compared to the same quarter last year. Read the conference call transcript. How will Solventum's stock buyback program work? Solventum's board approved a share repurchase program on Thursday, November 20th 2025, which permits the company to repurchase $1 billion in shares, according to EventVestor. This means that the company could purchase up to 7.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its shares are undervalued. Who are Solventum's major shareholders? Solventum's top institutional investors include State Street Corp (3.31%), Boston Partners (2.11%), Equity Investment Corp (0.51%) and Goldman Sachs Group Inc. (0.48%). View institutional ownership trends. How do I buy shares of Solventum? Shares of SOLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Solventum own? Based on aggregate information from My MarketBeat watchlists, some other companies that Solventum investors own include 3M (MMM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Altria Group (MO), Pfizer (PFE), ExxonMobil (XOM) and Johnson & Johnson (JNJ). Company Calendar Last Earnings11/05/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SOLV's financial health is in the Green zone, according to TradeSmith. SOLV has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Supplies Current SymbolNYSE:SOLV Previous SymbolNYSE:SOLV CIK1964738 Webwww.solventum.com Phone651-733-1110FaxN/AEmployees20,000Year Founded2023Price Target and Rating Average Price Target for Solventum$90.27 High Price Target$113.00 Low Price Target$35.00 Potential Upside/Downside+1.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$0.89 Trailing P/E Ratio12.60 Forward P/E Ratio11.86 P/E Growth1.26Net Income$1.56 billion Net Margins1.91% Pretax Margin2.09% Return on Equity25.03% Return on Assets8.65% Debt Debt-to-Equity Ratio0.99 Current Ratio1.03 Quick Ratio0.72 Sales & Book Value Annual Sales$8.33 billion Price / Sales1.81 Cash Flow$8.98 per share Price / Cash Flow9.88 Book Value$28.31 per share Price / Book3.13Miscellaneous Outstanding Shares169,740,000Free Float169,332,000Market Cap$15.06 billion OptionableOptionable Beta0.69 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:SOLV) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solventum Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Solventum With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.